(Q43150818)

14 November 2017

Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes (English)

1 reference

14 November 2017

0 references

0 references

1 reference

1 reference

9

1 reference

14 November 2017

Dilip K Deb

1

1 reference

14 November 2017

Tao Sun

2

1 reference

14 November 2017

Kari E Wong

3

1 reference

14 November 2017

Zhongyi Zhang

4

1 reference

14 November 2017

Gang Ning

5

1 reference

14 November 2017

Yan Zhang

6

1 reference

14 November 2017

Juan Kong

7

1 reference

14 November 2017

Helen Shi

8

1 reference

14 November 2017

Yan Chun Li

10

1 reference

14 November 2017

language of work or name

English

0 references

publication date

24 February 2010

1 reference

14 November 2017

1 reference

14 November 2017

77

1 reference

14 November 2017

11

1 reference

14 November 2017

1000-1009

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2010.22

14 November 2017

0 references

cites work

Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Activation of the renin-angiotensin system within podocytes in diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Direct renin inhibition with aliskiren in hypertension and target organ damage

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Analogs of 1alpha,25-dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Diabetic kidney disease in thedb/dbmouse

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Role of podocyte slit diaphragm as a filtration barrier

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Leptin attenuates gene expression for renal 25-hydroxyvitamin D3-1alpha-hydroxylase in mice via the long form of the leptin receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

The podocyte's response to injury: role in proteinuria and glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Predicting diabetic nephropathy in insulin-dependent patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Transcription factor-kappa B (NF-kappa B) and renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

The intrarenal renin-angiotensin system and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Renoprotective role of the vitamin D receptor in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Amelioration of diabetic nephropathy in SPARC-null mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.22

7 January 2021

Identifiers

DOI

10.1038/KI.2010.22

1 reference

14 November 2017

1 reference